Swift, Imogen J.
Rademakers, Rosa
Finch, NiCole
Baker, Matt
Ghidoni, Roberta
Benussi, Luisa
Binetti, Giuliano
Rossi, Giacomina
Synofzik, Matthis
Wilke, Carlo
Mengel, David
Graff, Caroline
Takada, Leonel T.
Sánchez-Valle, Raquel
Antonell, Anna
Galimberti, Daniela
Fenoglio, Chiara
Serpente, Maria
Arcaro, Marina
Schreiber, Stefanie
Vielhaber, Stefan
Arndt, Philipp
Santana, Isabel
Almeida, Maria Rosario
Moreno, Fermín
Barandiaran, Myriam
Gabilondo, Alazne
Stubert, Johannes
Gómez-Tortosa, Estrella
Agüero, Pablo
Sainz, M. José
Gohda, Tomohito
Murakoshi, Maki
Kamei, Nozomu
Kittel-Schneider, Sarah
Reif, Andreas
Weigl, Johannes
Jian, Jinlong
Liu, Chuanju
Serrero, Ginette
Greither, Thomas
Theil, Gerit
Lohmann, Ebba
Gazzina, Stefano
Bagnoli, Silvia
Coppola, Giovanni
Bruni, Amalia
Quante, Mirja
Kiess, Wieland
Hiemisch, Andreas
Jurkutat, Anne
Block, Matthew S.
Carlson, Aaron M.
Bråthen, Geir
Sando, Sigrid Botne
Grøntvedt, Gøril Rolfseng
Lauridsen, Camilla
Heslegrave, Amanda
Heller, Carolin
Abel, Emily
Gómez-Núñez, Alba
Puey, Roger
Arighi, Andrea
Rotondo, Enmanuela
Jiskoot, Lize C.
Meeter, Lieke H. H.
Durães, João
Lima, Marisa
Tábuas-Pereira, Miguel
Lemos, João
Boeve, Bradley
Petersen, Ronald C.
Dickson, Dennis W.
Graff-Radford, Neill R.
LeBer, Isabelle
Sellami, Leila
Lamari, Foudil
Clot, Fabienne
Borroni, Barbara
Cantoni, Valentina
Rivolta, Jasmine
Lleó, Alberto
Fortea, Juan
Alcolea, Daniel
Illán-Gala, Ignacio
Andres-Cerezo, Lucie
Van Damme, Philip
Clarimon, Jordi
Steinacker, Petra
Feneberg, Emily
Otto, Markus
van der Ende, Emma L.
van Swieten, John C.
Seelaar, Harro
Zetterberg, Henrik
Sogorb-Esteve, Aitana
Rohrer, Jonathan D.
Article History
Received: 27 October 2023
Accepted: 25 February 2024
First Online: 28 March 2024
Declarations
:
: The London Queen Square Ethics committee approved the study. The study complies with the Declaration of Helsinki.
: All participants provided written informed consent at enrolment including consent to publication.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). JDR has served on medical advisory boards and consultancy for Alector, Arkuda Therapeutics, Wave Life Sciences, and Prevail Therapeutics. Consultancy for UCB, AC Immune, Astex Pharmaceuticals, Biogen, Takeda and Eisai. SKS has received author’s and advisory honoraria from Takeda/Shire and Medice Arzneimittel Pütter GmbH in the last 3 years. AL participated in advisory boards from Biogen, Eisai, Fujirebio-Europe, Grifols, Novartis, Roche, Otsuka Pharmaceutical, Nutricia, Zambón, y NovoNordisk. AL declares a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease). DA participated in advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U. and Esteve Pharmaceuticals S.A. DA declares a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease). MS has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra,and Lilly, all unrelated to the present manuscript. IIG participated in advisory boards from UCB Pharma S.A., and received speaker honoraria from Nutricia, Kern Pharma S., Krka Farmacéutica S.L., Zambon S.A.U. and Esteve Pharmaceuticals S.A.